OAC
MCRB icon

OMERS Administration Corp’s Seres Therapeutics MCRB Stock Holding History

OMERS Administration Corp’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,400
Closed -$214K – 1144
2025
Q4 		$214K Buy
+14,400
New +$251K ﹤0.01% 899
2015
Q3 		– Sell
-495
Closed -$411K – 451
2015
Q2 		$411K Buy
+495
New +$432K 0.02% 365

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OMERS Administration Corp's MCRB Position: Q1 2026 in Review

OMERS Administration Corp sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 14,400 shares — an estimated $214K sold.

OMERS Administration Corp first reported a position in MCRB in Q2 2015 and held it in 2 quarters. The position peaked at $411K in Q2 2015. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • OMERS Administration Corp reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 14,400 Seres Therapeutics shares in Q1 2026, an estimated $214K.
  • OMERS Administration Corp first reported a position in Seres Therapeutics in Q2 2015 and held it in 2 quarters.
  • OMERS Administration Corp's Seres Therapeutics position peaked at $411K in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.